Of 10 prespecified secondary outcomes, 8 showed no significant difference. The primary outcome occurred in 59 patients (3.9%) receiving ticagrelor monotherapy after 3‐month DAPT and in 89 patients (5.9%) receiving ticagrelor‐based 12‐month DAPT (absolute difference, ‐1.98% hazard ratio, 0.66 P = .01). Results: Among 3056 patients who were randomized (mean age, 61 years 628 women 36% ST‐elevation myocardial infarction), 2978 patients (97.4%) completed the trial. Prespecified secondary outcomes included major bleeding and major adverse cardiac and cerebrovascular events.
Main Outcomes and Measures: The primary outcome was a 1‐year net adverse clinical event, defined as a composite of major bleeding and adverse cardiac and cerebrovascular events (death, myocardial infarction, stent thrombosis, stroke, or target‐vessel revascularization). Interventions: Patients were randomized to receive ticagrelor monotherapy (90 mg twice daily) after 3‐month DAPT (n = 1527) or ticagrelor‐based 12‐month DAPT (n = 1529).
#Tico trial trial#
Objective: To determine whether switching to ticagrelor monotherapy after 3 months of DAPT reduces net adverse clinical events compared with ticagrelor‐based 12‐month DAPT in patients with ACS treated with drug‐eluting stents.ĭesign, Setting, and Participants: A randomized multicenter trial was conducted in 3056 patients with ACS treated with drug‐eluting stents between August 2015 and October 2018 at 38 centers in South Korea. However, the strategy of ticagrelor monotherapy has not been exclusively evaluated in patients with acute coronary syndromes (ACS). Importance: Discontinuing aspirin after short‐term dual antiplatelet therapy (DAPT) was evaluated as a bleeding reduction strategy.
0 kommentar(er)
